Home › All Companies › BICX

BioCorRx Inc. (BICX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-02

Key Insights

  • BioCorRx Inc. has entered into a stock exchange agreement with its majority-owned subsidiary BioCorRx Pharmaceuticals, Inc., which is intended to help the company acquire full control of the subsidiary.
  • The exchange of shares between BioCorRx Inc. and the shareholders is structured as a tax-free reorganization under Section 368(a)(1)(B) of the Internal Revenue Code.
  • The shareholders who are transferring their BioCorRx Pharmaceuticals shares to the parent company are also being granted certain registration rights for the parent company shares they receive in return.
Sentiment: Positive Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-03-31

Key Insights

  • The company entered into multiple amendments to a promissory note, extending the maturity date and issuing additional restricted stock to the debt holder. This suggests the company may be facing liquidity or financing challenges.
  • The company has a history of raising capital through the issuance of common stock, preferred stock, and convertible securities. This ongoing need for financing could indicate difficulties in generating sufficient revenue and cash flow.
  • The company's financial statements show accumulated losses and a reliance on external funding, which raises concerns about its long-term viability and ability to become profitable.
Sentiment: Negative Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.